<?xml version='1.0' encoding='utf-8'?>
<document id="28685622"><sentence text="Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor." /><sentence text="1" /><sentence text=" 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl) acetamide (PF-06282999) is a member of the thiouracil class of irreversible inactivators of human myeloperoxidase enzyme and a candidate for the treatment of cardiovascular disease"><entity charOffset="1-88" id="DDI-PubMed.28685622.s3.e0" text="2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl) acetamide" /><entity charOffset="90-101" id="DDI-PubMed.28685622.s3.e1" text="PF-06282999" /><entity charOffset="122-132" id="DDI-PubMed.28685622.s3.e2" text="thiouracil" /><pair ddi="false" e1="DDI-PubMed.28685622.s3.e0" e2="DDI-PubMed.28685622.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28685622.s3.e0" e2="DDI-PubMed.28685622.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28685622.s3.e0" e2="DDI-PubMed.28685622.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28685622.s3.e1" e2="DDI-PubMed.28685622.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28685622.s3.e1" e2="DDI-PubMed.28685622.s3.e2" /></sentence><sentence text=" PF-06282999 is an inducer of CYP3A4 mRNA and midazolam-1'-hydroxylase activity in human hepatocytes, which is consistent with PF-06282999-dose dependent decreases in mean maximal plasma concentrations (Cmax) and area under the plasma concentration time curve (AUC) of midazolam in humans following 14-day treatment with PF-06282999"><entity charOffset="269-278" id="DDI-PubMed.28685622.s4.e0" text="midazolam" /></sentence><sentence text=" 2" /><sentence text=" In the present study, the biochemical mechanism(s) of CYP3A4 induction by PF-06282999 was studied" /><sentence text=" Incubations in reporter cells indicated that PF-06282999 selectively activated human pregnane X receptor (PXR)" /><sentence text=" Treatment of human HepaRG cells with PF-06282999 led to ∼14-fold induction in CYP3A4 mRNA and 5-fold increase in midazolam-1'-hydroxylase activity, which was nullified in PXR-knock out HepaRG cells" /><sentence text=" TaqMan® gene expression analysis of human hepatocytes treated with PF-06282999 and the prototypical PXR agonist rifampin demonstrated increases in mRNA for CYP3A4 and related CYPs that are regulated by PXR" /><sentence text=" 3" /><sentence text=" Docking studies using a published human PXR crystal structure provided insights into the molecular basis for PXR activation by PF-06282999" /><sentence text=" Implementation of PXR transactivation assays in a follow-on discovery campaign should aid in the identification of back-up compounds devoid of PXR activation and CYP3A4 induction liability" /><sentence text="" /></document>